This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: An application of two MIFs-based tools (Volsurf plus and Pentacle) to binary QSAR: The case of a palinurin-related data set of non-ATP competitive Glycogen Synthase Kinase 3 beta (GSK-3 beta) inhibitors

Title An application of two MIFs-based tools (Volsurf plus and Pentacle) to binary QSAR: The case of a palinurin-related data set of non-ATP competitive Glycogen Synthase Kinase 3 beta (GSK-3 beta) inhibitors
Abstract

VolSurf+ and GRIND descriptors extract the information present in MIFs calculated by GRID: the first are simpler to interpret and generally applied to ADME-Tox topics, whereas the latter are more sophisticated and thus more suited for pharmacodynamics events. Here we present a study which compares binary QSAR models obtained with VolSurf+ descriptors and GRIND for a data set of non-ATP competitive GSK-3β inhibitors chemically related to palinurin for which the biological activity is expressed in binary format. Results suggest not only that the simpler Volsurf+ descriptors are good enough to predict and chemically interpret the investigated phenomenon but also a bioactive conformation of palinurin which may guide future design of ATP non-competitive GSK-3 inhibitors.

Apa Reference Ermondi, G., Caron, G., Pintos, I. G., Gerbaldo, M., Pérez, M., Pérez, D. I., Gándara, Z., Martínez, A., Gómez, G., & Fall, Y. (2011). An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: The case of a palinurin-related data set of non-ATP competitive Glycogen Synthase Kinase 3β (GSK-3β) inhibitors. European Journal of Medicinal Chemistry, 46(3), 860–869. 10.1016/j.ejmech.2010.12.024
Doi 10.1016/j.ejmech.2010.12.024
Publication Date Mar 2011
Publication Type Article
Researcher Ana Martínez
Ontology Drug Discovery and design
Research Groups Translational Medicinal and Biological Chemistry
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home